News Center

Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China Received Clearance By NMPA

Release time：2024-05-24 17:00

Suzhou, May 24, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia (“AGA”) in China (the “Clinical Trial”) was cleared by the National Medical Products Administration (the “NMPA”) recently.

 

The Clinical Trial is aimed to evaluate the efficacy and safety of KX-826 tincture 1.0% for the topical treatment of male adults with AGA in China. The Company’s preclinical studies have shown that the KX-826 tincture 1.0% has significantly increased the retention concentration of the tincture on human scalp cells compared to the KX-826 tincture 0.5% used in the previous phase III clinical trial, and is expected to enhance the clinical efficacy.

 

Dr. Youzhi Tong, the founder, chairman and CEO of Kintor Pharma, said,"KX-826 is one of the core drugs of the Group. Since its development, it has completed multiple clinical trials for the treatment of male and female AGA in China and the United States, which has demonstrated excellent safety profile and efficacy trend. Our Company will further explore the value of KX-826 for AGA. In the meanwhile, we also conducting or planning multiple clinical trials of KX-826 for the treatment of AGA and acne, continuing to explore the value of KX-826 in the field of dermatology."

Previous:

KX-826 Received The INCI Designation

Next:

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

recommend News

Kintor